7URV

FMC63 scFv in complex with soluble CD19

7URV の概要

• エントリーDOI: 10.2210/pdb7urv/pdb
• EMDBエントリー: 26719
• 分子名称: B-lymphocyte antigen CD19, FMC63 single-chain variable fragment (2 entities in total)
• 機能のキーワード: complex, car-t, protein binding
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 54101.84

構造登録者

Meyerson, J.,He, C. (登録日: 2022-04-22, 公開日: 2023-02-15, 最終更新日: 2025-05-14)

主引用文献

He, C.,Mansilla-Soto, J.,Khanra, N.,Hamieh, M.,Bustos, V.,Paquette, A.J.,Garcia Angus, A.,Shore, D.M.,Rice, W.J.,Khelashvili, G.,Sadelain, M.,Meyerson, J.R.
CD19 CAR antigen engagement mechanisms and affinity tuning.
Sci Immunol, 8:eadf1426-eadf1426, 2023

PubMed Abstract: Chimeric antigen receptor (CAR) T cell therapy relies on T cells that are guided by synthetic receptors to target and lyse cancer cells. CARs bind to cell surface antigens through an scFv (binder), the affinity of which is central to determining CAR T cell function and therapeutic success. CAR T cells targeting CD19 were the first to achieve marked clinical responses in patients with relapsed/refractory B cell malignancies and to be approved by the U.S. Food and Drug Administration (FDA). We report cryo-EM structures of CD19 antigen with the binder FMC63, which is used in four FDA-approved CAR T cell therapies (Kymriah, Yescarta, Tecartus, and Breyanzi), and the binder SJ25C1, which has also been used extensively in multiple clinical trials. We used these structures for molecular dynamics simulations, which guided creation of lower- or higher-affinity binders, and ultimately produced CAR T cells endowed with distinct tumor recognition sensitivities. The CAR T cells exhibited different antigen density requirements to trigger cytolysis and differed in their propensity to prompt trogocytosis upon contacting tumor cells. Our work shows how structural information can be applied to tune CAR T cell performance to specific target antigen densities.

PubMed: 36867678
DOI: 10.1126/sciimmunol.adf1426

実験手法

ELECTRON MICROSCOPY (3.05 Å)